GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » Intrinsic Value: Projected FCF

Jenscare Scientific Co (HKSE:09877) Intrinsic Value: Projected FCF : HK$0.00 (As of Jun. 01, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-01), Jenscare Scientific Co's Intrinsic Value: Projected FCF is HK$0.00. The stock price of Jenscare Scientific Co is HK$8.51. Therefore, Jenscare Scientific Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Jenscare Scientific Co's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:09877's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.515
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Jenscare Scientific Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Jenscare Scientific Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jenscare Scientific Co Intrinsic Value: Projected FCF Chart

Jenscare Scientific Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
- - - - -

Jenscare Scientific Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Jenscare Scientific Co's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Jenscare Scientific Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jenscare Scientific Co's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jenscare Scientific Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Jenscare Scientific Co's Price-to-Projected-FCF falls into.


;
;

Jenscare Scientific Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Jenscare Scientific Co  (HKSE:09877) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Jenscare Scientific Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=8.51/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jenscare Scientific Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Jenscare Scientific Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Jenscare Scientific Co Business Description

Traded in Other Exchanges
N/A
Address
No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.
Executives
Lv Shiwen 2501 Other
Li Hui 2501 Other
Shanghai Shidi Industrial Development Co., Ltd. 2501 Other
Ningbo Linfeng Biotechnology Co., Ltd. 2101 Beneficial owner
Onez International Limited 2101 Beneficial owner
Pan Fei 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Trinity Elite I International Limited 2201 Interest of corporation controlled by you
Ningbo Dixiang Venture Capital Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Jiachen Investment Co.,ltd 2201 Interest of corporation controlled by you
Ningbo Sangdi Investment Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Yize Medical Technology Co., Limited 2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership) 2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership) 2101 Beneficial owner

Jenscare Scientific Co Headlines

No Headlines